Kylo 03
Alternative Names: Kylo-03Latest Information Update: 16 Aug 2024
At a glance
- Originator Kylonova (Xiamen) Biopharma
- Class Antineoplastics; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 29 Jul 2024 Kylonova (Xiamen) Biopharma has patent protection for Nano-Lipid Particle (NPDP), Multi-Valent Import platform (MVIP) and Lipid-Coupling Delivery platform (LCDP) (Kylonova (Xiamen) Biopharma pipeline, July 2024)
- 29 Jul 2024 Preclinical trials in Solid tumours in China (unspecified route) prior to July 2024 (Kylonova Biopharma pipeline, July 2024)